|1.||Baselga, José: 13 articles (02/2015 - 03/2010)|
|2.||Swain, Sandra M: 13 articles (02/2015 - 02/2006)|
|3.||Ross, Graham: 12 articles (02/2015 - 01/2012)|
|4.||Cortés, Javier: 10 articles (02/2015 - 01/2012)|
|5.||Clark, Emma: 8 articles (02/2015 - 01/2012)|
|6.||Sliwkowski, Mark X: 7 articles (01/2014 - 04/2005)|
|7.||Hasmann, Max: 7 articles (09/2013 - 07/2005)|
|8.||Knott, Adam: 6 articles (07/2014 - 01/2012)|
|9.||Schneeweiss, Andreas: 5 articles (07/2015 - 03/2013)|
|10.||Miles, David: 5 articles (07/2014 - 03/2010)|
|1.||Breast Neoplasms (Breast Cancer)
09/01/2012 - "The pharmacokinetics (PK), safety, and efficacy of T-DM1 combined with pertuzumab were studied in a phase 1b/2 trial in 67 patients with HER2-positive, locally advanced or metastatic breast cancer (MBC). "
01/01/2015 - "Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy."
12/01/2014 - "This review presents the mechanisms of action as well as phase I, II and III clinical data describing the safety and efficacy of pertuzumab and T-DM1 for HER2-positive breast cancer. "
02/12/2012 - "Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer."
01/15/2014 - "In patients with HER2-positive locally advanced or metastatic breast cancer (mBC), T-DM1 was dose-escalated with a fixed standard pertuzumab dose in a 3+3 phase Ib/II study design. "
01/01/2015 - "It is now imperative to identify which tumors need dual HER2 targeting and to study the activity of pertuzumab in combination with other HER-targeted agents, including anti-HER1, -HER3 or -HER4, which could also prove useful in HER2-normal cancers. "
10/01/2014 - "To characterize the population pharmacokinetics (PK) of pertuzumab across clinical trials in a variety of solid tumors, evaluate the potential impact of patient characteristics on PK, and confirm the appropriateness of the fixed (non-weight-based) dose. "
09/01/2013 - "In this study, we investigated the effect of combining T-DM1 and pertuzumab on xenografted gastric tumors. "
09/01/2012 - "Eligible studies were prospective phase II-III clinical trials using pertuzumab in cancer patients. "
04/01/2009 - "This study evaluated the toxicity, pharmacokinetics and anti-tumor activities of pertuzumab in Japanese patients with solid tumors. "
|3.||Stomach Neoplasms (Stomach Cancer)
09/01/2013 - "These findings suggest that T-DM1 in combination with pertuzumab shows significant antitumor activity by increasing AKT signal inhibition and ADCC in HER2-positive gastric cancers. "
08/01/2011 - "We showed the significantly enhanced efficacy of pertuzumab combining with trastuzumab for HER2 overexpressing gastric cancer through the potentiation of cell growth inhibition, apoptosis activity, cell killing activity by ADCC, and antiangiogenic activity. "
08/01/2011 - "This study suggests the clinical benefit of combination therapy with pertuzumab and trastuzumab for patients with HER2-positive gastric cancers."
09/01/2013 - "Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model."
08/12/2014 - "Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). "
|4.||Prostatic Neoplasms (Prostate Cancer)
12/01/2003 - "The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer."
09/01/2012 - "Data from a total of 1,726 patients (pertuzumab, n = 1,157; controls, n = 569) with breast, ovarian, and prostate cancers from eight clinical trials were included for analysis. "
04/01/2007 - "Pertuzumab brake for prostate cancer?"
02/20/2007 - "The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy. "
01/20/2007 - "Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer."
05/10/2012 - "All 29 patients enrolled for pertuzumab monotherapy experienced disease progression. "
06/01/2014 - "Median time to development of CNS metastases as first site of disease progression was 11.9 months in the placebo arm and 15.0 months in the pertuzumab arm; hazard ratio (HR) = 0.58, 95% confidence interval (CI) 0.39-0.85, P = 0.0049. "
06/01/2014 - "The incidence of CNS metastases as first site of disease progression was similar between arms; placebo arm: 51 of 406 (12.6%), pertuzumab arm: 55 of 402 (13.7%). "
05/10/2012 - "Seventeen patients with disease progression continued to receive pertuzumab (at the same dose), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks). "
03/01/2010 - "Patients with advanced HER2-positive breast cancer in whom disease progression had occurred during prior trastuzumab-based therapy received trastuzumab weekly (4 mg/kg loading dose, then 2 mg/kg every week) or every 3 weeks (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) and pertuzumab every 3 weeks (840 mg loading dose, then 420 mg every 3 weeks). "
|3.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||erlotinib (CP 358,774)
|8.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)